Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
111YI 45 Debt-to-Equity is -0.38 as of Mar. 2026. GuruFocus rates YI with a GF Score™ of 45/100 and a GF Value™ of $6.64 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 99 Medical Distribution companies, 111 ranks worse than 1010100% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 111's Debt-to-Equity or its related term are showing as below:
YI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.36 Med: -0.37 Max: 2.16
Current: -0.38
During the past 10 years, the highest Debt-to-Equity Ratio of 111 was 2.16. The lowest was -3.36. And the median was -0.37.
YI's Debt-to-Equity is not ranked
in the Medical Distribution industry.
Industry Median: 0.48
vs YI: -0.38
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
111 Debt-to-Equity Related Terms
111 Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for 111's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, 111's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
111 Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 111's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 111's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
111 (YI) has a Debt-to-Equity of -0.38 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 111 and its competitors. According to the industry distribution chart, 111 ranks #999999 out of 99 companies in the Medical Distribution industry.
Is 111's Debt-to-Equity too high?
111's current Debt-to-Equity is -0.38. Based on the distribution chart, 111 ranks #999999 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 111 has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 111's Debt-to-Equity compare to COSM and HKPD?
According to the Medical Distribution industry distribution chart, 111 ranks #999999 out of 99 companies for Debt-to-Equity. This places 111 in the lower half of its industry. The industry median Debt-to-Equity is 0.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 111 and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 111's current Debt-to-Equity is -0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 111 stock overvalued right now?
Based on GuruFocus' analysis, 111 (YI) is currently considered Possible Value Trap. The stock's GF Value™ is $6.64, compared to a current price of $3.75 — trading 43.6% below its estimated fair value. The current Debt-to-Equity is -0.38. 111's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 111 (YI), the current Debt-to-Equity is -0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 111 (YI) Overvalued in 2026?
Based on GuruFocus' analysis, 111 stock appears to be undervalued.
The current stock price of $3.75 is trading 43.6% below its estimated GF Value™ of $6.64.
GuruFocus considers 111 to be Possible Value Trap.
Key valuation signals for YI:
Debt-to-Equity: -0.38
GF Value™: $6.64 vs. price of $3.75 (43.6% below fair value)
No single metric tells the full story. See the YI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
45GF Score
Get the complete analysis for YI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YI has been successfully added to your 
